Brokerages predict that Viking Therapeutics Inc (NASDAQ:VKTX) will post ($0.11) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Viking Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Viking Therapeutics posted earnings of ($0.14) per share during the same quarter last year, which would indicate a positive year over year growth rate of 21.4%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, March 6th.
On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.44) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.41). For the next year, analysts forecast that the company will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.55) to ($0.39). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.01.
Several analysts have recently weighed in on the stock. SunTrust Banks assumed coverage on shares of Viking Therapeutics in a report on Friday, July 20th. They set a “buy” rating and a $14.00 price objective for the company. Roth Capital raised their price objective on shares of Viking Therapeutics from $13.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, September 19th. Maxim Group reaffirmed a “buy” rating and set a $28.00 price objective on shares of Viking Therapeutics in a report on Thursday. BidaskClub lowered shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 3rd. Finally, Raymond James set a $43.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a report on Wednesday, September 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Viking Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $28.17.
In related news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total value of $5,034,171.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.90% of the company’s stock.
Several institutional investors have recently modified their holdings of the stock. American International Group Inc. increased its holdings in shares of Viking Therapeutics by 21.3% in the third quarter. American International Group Inc. now owns 34,403 shares of the biotechnology company’s stock valued at $599,000 after purchasing an additional 6,036 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Viking Therapeutics by 12.0% in the third quarter. Wells Fargo & Company MN now owns 65,810 shares of the biotechnology company’s stock valued at $1,146,000 after acquiring an additional 7,037 shares during the last quarter. First Mercantile Trust Co. bought a new position in Viking Therapeutics in the third quarter valued at approximately $131,000. Janney Montgomery Scott LLC bought a new position in Viking Therapeutics in the second quarter valued at approximately $114,000. Finally, Strs Ohio bought a new position in Viking Therapeutics in the second quarter valued at approximately $120,000. 53.56% of the stock is owned by institutional investors and hedge funds.
NASDAQ VKTX opened at $12.33 on Wednesday. The company has a market cap of $833.44 million, a PE ratio of -15.61 and a beta of 2.92. Viking Therapeutics has a 1-year low of $2.24 and a 1-year high of $24.00.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Read More: How is inflation measured?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.